Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy.

  • Investors will get in cash for every Zogenix share, plus a potential $2 per share payment if Zogenix's Fintepla drug gets regulatory approval for Lennox-Gastaut syndrome by the end of 2023.

  • The initial payment is 66% higher than Tuesday's closing price of $15.64.

  • Lennox-Gastaut syndrome is an orphan disease that causes seizures.

  • Related: Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy.

  • Fintepla has already received regulatory approval in the U.S. and European Union for seizures caused by Dravet syndrome, a rare form of epilepsy.

  • UCB said it would finance the deal with cash and a new term loan.

  • In addition to contributing to UCB's revenue growth after closing, the Zogenix deal is expected to be accretive to UCB's earnings from 2023 onwards.

  • Lazard and Barclays are UCB's financial advisors, while Bank of America Securities and SVB Leerink advised Zogenix.

  • Price Action: ZGNX shares surged 59.9% at $25.00 during the premarket session on the last check Wednesday.

See more from Benzinga

  • Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients

  • Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer

© 2022 Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888